NCT07382349Recruiting
A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease
Randomized Controlled Trial of Electronic Clinical Decision Support Systems for Improving Care Management and Clinical Outcomes for Adults With Steatotic Liver Disease
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
The overall objectives of this study are to determine the effectiveness of a participant-specific guided electronic decision support system on provider decision making for participants with metabolic-dysfunction associated steatotic liver disease (MASLD), and to determine the acceptance and barriers for use of an electronic health record embedded algorithm for MASLD care management within ambulatory primary care, endocrinology, and general gastroenterology settings.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 7200 (estimated)
- First submitted
- 24 Jan 2026
- Start date
- 20 Jul 2026
- Primary completion date
- Feb 2030
- Lead sponsor
- Vanderbilt University Medical Center
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07382349
What you commit to
- Study type: Interventional
- Planned participants: 7200
- From 20 Jul 2026 to the primary completion date, Feb 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Solid Organ Transplant Recipient
- Existing Hepatology Relationship Evidenced by Prior Hepatology Visit Within 3 Years
- Receiving Palliative Care Services
Other illness
- Active Cancer Diagnoses
- Diagnoses for Alcohol-Related Conditions
Other
- Pregnant Individuals
Who the study is looking for
- Adult patients (age ≥ 18 years)
- Outpatient clinic visit (in-person or telemedicine) at a participating clinic site
- Demonstrated Screening Need due to High Risk Profile, which includes the following: Diagnostic Codes for MASLD or Hepatic Steatosis on Imaging PLUS at least one cardiometabolic risk factors; OR Chronically Elevated Liver Enzymes (\> 6 months); OR patient with impaired glycemic control (prediabetes/diabetes); OR 2 or more cardiometabolic risk factors present
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.